Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Phase 2 NFKB2 rearrangement-driven MM trial: predictor of sensitivity to PIs?

Sagar Lonial • 8 Dec 2019
ASH 2019
Multiple Myeloma Dexamethasone Ixazomib
PINR

Sagar Lonial, MD, FACP, Winship Cancer Institute at Emory University, Atlanta, GA, covers the phase 2 trial of ixazomib and dexamethasone vs. ixazomib, dexamethasone and lenalidomide, randomized with NFKB2 rearrangement (NCT02765854). This aimed to use NFKB2 status as a biomarker to predict for sensitivity to proteasome inhibitors (PIs). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Sagar Lonial

1:05
Real-world comparison of RVD vs D-RVD in newly diagnosed transplant-eligible multiple myeloma
Sagar Lonial • 9 Dec 2023
0:45
The addition of daratumumab to RVD deepens treatment responses in t(11;14) multiple myeloma
Sagar Lonial • 9 Dec 2023
1:06
DeRIVE trial update: DId vs DVd in newly diagnosed MM
Sagar Lonial • 9 Dec 2023
0:48
Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myeloma
Sagar Lonial • 7 Sep 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals